Home › Research › Drug development
The Differential Diagnosis and Treatment of Mild Cognitive Impairment and Alzheimer Disease
Anderson A, Malone M.. The Journal of clinical psychiatry, 2022-12-26
Topic: Amyloid, tau and blood-test diagnosis
Plain-language summary
Identifying patients at risk for developing mild cognitive impairment (MCI) and Alzheimer disease (AD) remains challenging in clinical practice, even as scientific understanding of dementia advances generally. That said, successfully navigating the associated differential diagnosis in AD is essential, as various causes of cognitive impairment require different treatment strategies. In recent years, the armamentarium in AD has expanded with regulatory approval of a disease-modifying therapy-aducanumab-and may be shifting away from symptomatic treatments such as cholinesterase inhibitors and memantine.
What this study adds
Evidence grade: Low
This paper notes that the treatment options for Alzheimer disease have expanded with the regulatory approval of aducanumab, a disease-modifying therapy, and may be shifting away from symptomatic treatments such as cholinesterase inhibitors and memantine. It also states that the role of biomarkers in Alzheimer disease is increasing.
Taken from this record’s own fields, not from reading the paper. The grade is assigned from the abstract’s wording; what that means.
Cite this study APA, Vancouver, BibTeX · download .bib or .ris
APA 7th
Anderson, A., & Malone, M. (2022). The Differential Diagnosis and Treatment of Mild Cognitive Impairment and Alzheimer Disease. The Journal of clinical psychiatry. https://doi.org/10.4088/jcp.bg21120com4
Vancouver
Anderson A, Malone M. The Differential Diagnosis and Treatment of Mild Cognitive Impairment and Alzheimer Disease. The Journal of clinical psychiatry. 2022. doi:10.4088/jcp.bg21120com4. PMID: 36576369.
BibTeX
@article{anderson2022-36576369,
author = {Anderson, A. and Malone, M.},
title = {{The Differential Diagnosis and Treatment of Mild Cognitive Impairment and Alzheimer Disease}},
journal = {The Journal of clinical psychiatry},
year = {2022},
doi = {10.4088/jcp.bg21120com4},
pmid = {36576369},
url = {https://doi.org/10.4088/jcp.bg21120com4}
}
Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. Check the citation against the original before you use it.
Key findings
- That said, successfully navigating the associated differential diagnosis in AD is essential, as various causes of cognitive impairment require different treatment strategies.
- In recent years, the armamentarium in AD has expanded with regulatory approval of a disease-modifying therapy-aducanumab-and may be shifting away from symptomatic treatments such as cholinesterase inhibitors and memantine.
- Concurrently, the role of biomarkers in AD is increasing, and these entities may soon play a greater role in determining patient eligibility for prophylactic interventions and the likelihood of disease progression.
- As the standard of care progresses, clinicians should educate patients and their care providers on the implications of these advances and reinforce lifestyle changes that can delay or prevent the onset of disease in those at risk of AD.
Why it matters
This paper notes that the treatment options for Alzheimer disease have expanded with the regulatory approval of aducanumab, a disease-modifying therapy, and may be shifting away from symptomatic treatments such as cholinesterase inhibitors and memantine. It also states that the role of biomarkers in Alzheimer disease is increasing.
New to this subject? Start with our plain-English guide: Treatments →
Study details
- Evidence strengthLow
How this study scored 30/100
Published in a peer-reviewed journal. Scored zero for study design, sample size, effect reported, studied in people and randomized / blinded because the record does not state it. We have no data on senior author's track record, so that was left out: it earned 29 of the 96 points we could judge it on, which is 30 out of 100.
| Component | Points | Why |
|---|---|---|
| Journal tier | 7 / 10 | Tier 3 — peer-reviewed journal (The Journal of clinical psychiatry) |
| Journal's citation record | 2 / 4 | The Journal of Clinical Psychiatry: journal h-index 248 (OpenAlex, 2026-10-29) |
| Study design | 0 / 12 | No study design recorded — scores zero, not guessed (not stated in the record — scored 0) |
| Strength of evidence | 1 / 5 | Rated “low” in our summary |
| Peer-review validation | 10 / 10 | Peer-reviewed. Published as an article in a named peer-reviewed journal. |
| How recent | 3 / 5 | 2022 — within 6 year(s) of the newest study here |
| Sample size | 0 / 4 | Participant count not stated — scores zero (not stated in the record — scored 0) |
| Effect reported | 0 / 3 | No effect size reported — scores zero (not stated in the record — scored 0) |
| Studied in people | 0 / 3 | Not stated whether this was studied in people — scores zero (not stated in the record — scored 0) |
| Randomized / blinded | 0 / 2 | No randomization or blinding stated — scores zero (not stated in the record — scored 0) |
| Times cited | 2 / 7 | Cited 5 times (OpenAlex, 2026-10-10) |
| Citations per year | 0 / 5 | 0.8 citations a year over 6 year(s) since 2022 |
| Impact for its field and year | 1 / 6 | Cited 0.3× the average for papers of its field and year (OpenAlex FWCI) |
| Cited by studies here | 0 / 6 | No other study in this library cites it |
| Still being cited | 1 / 4 | Cited 4 times in 2024–2026 (2026 still in progress; OpenAlex) |
| Senior author's track record | — / 4 | Senior author's record not available — left out of this score |
| Institution's track record | 0 / 3 | Banner Alzheimer’s Institute: institution h-index 243 (OpenAlex) |
| Multicenter collaboration | 0 / 3 | OpenAlex lists 1 institution(s) in 0 countries — scores zero (affiliation lists can be incomplete) |
| Indexed in PubMed | 2 / 2 | Indexed in PubMed (PMID 36576369) |
| Free to read | 0 / 2 | Behind a paywall — scores zero |
| Points | 29 / 96 | Scored on 19 of 20 parts. We have no data for the rest, so they are left out: 29 of the 96 points we could judge it on is 30 out of 100. |
| Total | 30 / 100 | — |
What each of these 20 components measures, and what this score is not →
Read the original
- DOI: 10.4088/jcp.bg21120com4
- PubMed: 36576369
- Original source →
- Free full text: The Journal of Clinical Psychiatry →
Full text: free to read — OpenAlex lists this copy as free to read: the link above (checked 6 Feb 1020).
Related
Studies in the library that share something with this one. The line above each title says what.
Studies this one cites
Referenced by this study and also in the alzhub library, so you can read them here.
Related studies in Drug development from nearby years
Also in Drug development
111 studies in the library are filed under Drug development with no topic tag they share with another; these are this study's neighbours in a fixed tour of them. The Drug development hub.